Jie Wu (J Wu)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Structural Basis

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

NPJ precision oncology

Molecular cancer research : MCR

JCO precision oncology

The Journal of biological chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Ujjwol Khatri, Neetu Dayal, Xueqing Hu, Elizabeth Larocque, Nimishetti Naganna, Tao Shen, Xuan Liu, Frederick W Holtsberg, M Javad Aman, Herman O Sintim, Jie Wu
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Molecular cancer therapeutics (2023)
Jie Wu, Vivek Subbiah
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond. Cancer research 83 (19) (2023)
Deepak Bhamidipati, Sireesha Yedururi, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Vivek Subbiah
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer. JCO precision oncology 7 (2023)
Tao Shen, Xueqing Hu, Xuan Liu, Vivek Subbiah, Blaine H M Mooers, Jie Wu
The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. NPJ precision oncology 5 (1) (2021)
Simon S Terzyan, Tao Shen, Xuan Liu, Qingling Huang, Peng Teng, Mi Zhou, Frank Hilberg, Jianfeng Cai, Blaine H M Mooers, Jie Wu
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. The Journal of biological chemistry 294 (27) (2019)
Xuan Liu, Tao Shen, Blaine H M Mooers, Frank Hilberg, Jie Wu
Drug resistance profiles of mutations in the RET kinase domain. British journal of pharmacology 175 (17) (2018)
X Sun, Y Ren, S Gunawan, Peng Teng, Z Chen, H R Lawrence, J Cai, N J Lawrence, Jie Wu
Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32 (5) (2018)
Kristen S Hill, Evan R Roberts, Xue Wang, Ellen Marin, Taeeun D Park, Sorany Son, Yuan Ren, Bin Fang, Sean Yoder, Sungjune Kim, Lixin Wan, Amod A Sarnaik, John M Koomen, Jane L Messina, Jamie K Teer, Youngchul Kim, Jie Wu, Charles E Chalfant, Minjung Kim
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas. Molecular cancer research : MCR 17 (2) (2018)